Company: CERO
Filing Date: 2025-05-27
Form Type: POS AM
Source: 0001213900-25-047469
Chunk: 29

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-27
Form: POS AM
Chunk 29
---
 If all of the 2,100,000 shares of our Common Stock offered for resale by the Selling Securityholder under this prospectus were issued and outstanding as of May 19, 2025, such shares would represent approximately 7.6% of total number of shares of our 25,578,390 shares of fully-diluted Common Stock outstanding. The actual number of shares of our Common Stock issuable will vary depending on the then current market price of shares of our Common Stock sold to the Selling Securityholder in this offering and the number of shares of our Common Stock we ultimately elect to sell to the Selling Securityholder under the Keystone Purchase Agreements. If it becomes necessary for us to issue and sell to Keystone under the Keystone Purchase Agreements more than the 2,100,000 shares of our Common Stock being registered for resale under the Registration Statements in order to receive aggregate gross proceeds equal to $25.0 million under the Keystone Purchase Agreements, we must file with the SEC one or more additional registration statements to register under the Securities Act the resale by Keystone of any such additional shares of our Common Stock we wish to sell from time to time under the Keystone Purchase Agreements, which the SEC must declare effective, in each case before we may elect to sell any additional shares of our Common Stock under the Purchase Agreements. In addition, Keystone is not obligated to buy any Common Stock under the Keystone Purchase Agreements if such shares, when aggregated with all other Common Stock then beneficially owned by Keystone and its affiliates (as calculated pursuant to Section 13(d) of the Securities Exchange Act, and Rule 13d-3 promulgated thereunder), would result in Keystone beneficially owning Common Stock in excess of 4.99% of the then-outstanding shares of Common Stock. Our inability to access a portion or the full amount available under the Keystone Purchase Agreements, in the absence of any other financing sources, could have a material adverse effect on our business or results of operation. Keystone will pay less than the then-prevailing market price for our Common Stock, which could cause the price of our Common Stock to decline. The purchase price of our Common Stock to be sold to Keystone under the Keystone Purchase Agreements is derived from the market price of our Common Stock on Nasdaq. Shares to be sold to Keystone pursuant to the Keystone Purchase Agreements will be purchased at a discounted price. For example, we may effect sales to Keystone pursuant to a Fixed Purchase Notice (as defined below) at a purchase price equal